SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Significant Drop in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Rating) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 138,200 shares, a decline of 30.1% from the March 15th total of 197,800 shares. Currently, 0.4% of the company’s shares are short sold. Based […]

Related Keywords

,Silver Oak Securities Incorporated ,Hightower Advisors ,Biotherapeutics Company Profile ,Sab Biotherapeutics Inc ,Millennium Management ,Citadel Advisors ,Nasdaq ,Biotherapeutics Inc ,Get Rating ,Street Corp ,Oak Securities Incorporated ,Sab Biotherapeutics ,Nasdaq Sabs ,Sabs ,Medical ,Stocks ,Options ,Put ,Call ,